Companies › Scholar Rock
2 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apitegromab Growth/differentiation factor 8 inhibitor | MSTN | Phase 3 | Spinal Muscular Atrophy; Facioscapulohumeral Muscular Dystrophy | Jun 2028 |
| SRK-439 Activin A ligand trap | – | Phase 1 | Healthy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07444294 | SRK-439 | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07435129 | Apitegromab | Phase 2 | Facioscapulohumeral Muscular Dystrophy | Neurology | Jun 2028 |
| NCT07047144 | Apitegromab | Phase 2 | Spinal Muscular Atrophy | Neurology | Nov 2028 |
| NCT05626855 | Apitegromab | Phase 3 | Spinal Muscular Atrophy | Neurology | May 2029 |
Cash and short-term investments of $414m on 2026-09-30; operating cash outflow about $314m a year; runway about 16 months at that burn, to Jan 2028; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ensysce Biosciences Cartesian Therapeutics Epygenix Shaanxi Micot Pharmaceutical Technology Harmony Biosciences Management
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.